Switch theme
Sign up to access all valuation multiples
4basebio PLC is a life sciences group focused on therapeutic DNA for gene therapies and DNA vaccines and providing solutions for the effective and safe delivery of these DNA-based products to patients. Its country of operation is the UK. It is engaged in the manufacturing and supply of high-purity, synthetic DNA for research, therapeutic and pharmacological use.
2019
77
LTM Revenue $2.3M
LTM EBITDA -$17.4M
$241M
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
4basebio has a last 12-month revenue (LTM) of $2.3M and a last 12-month EBITDA of -$17.4M.
In the most recent fiscal year, 4basebio achieved revenue of $1.3M and an EBITDA of -$14.7M.
4basebio expects next 12-month revenue of XXX and NTM EBITDA of XXX
See 4basebio valuation multiples based on analyst estimates| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue | $2.3M | XXX | $1.3M | XXX | XXX | XXX |
| Gross Profit | $1.5M | XXX | $0.8M | XXX | XXX | XXX |
| Gross Margin | 68% | XXX | 68% | XXX | XXX | XXX |
| EBITDA | -$17.4M | XXX | -$14.7M | XXX | XXX | XXX |
| EBITDA Margin | -770% | XXX | -1176% | XXX | XXX | XXX |
| EBIT | -$19.0M | XXX | -$17.2M | XXX | XXX | XXX |
| EBIT Margin | -841% | XXX | -1371% | XXX | XXX | XXX |
| Net Profit | -$19.2M | XXX | -$16.6M | XXX | XXX | XXX |
| Net Margin | -850% | XXX | -1322% | XXX | XXX | XXX |
| Net Debt | XXX | XXX | n/a | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of May 30, 2025, 4basebio's stock price is GBP 11 (or $15).
4basebio has current market cap of GBP 172M (or $231M), and EV of GBP 179M (or $241M).
See 4basebio trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $241M | $231M | XXX | XXX | XXX | XXX | $-1.28 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Start Free TrialAs of May 30, 2025, 4basebio has market cap of $231M and EV of $241M.
4basebio's trades at 192.0x EV/Revenue multiple, and -16.3x EV/EBITDA.
Equity research analysts estimate 4basebio's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
4basebio has a P/E ratio of -12.0x.
See valuation multiples for 4basebio and 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $231M | XXX | $231M | XXX | XXX | XXX |
| EV (current) | $241M | XXX | $241M | XXX | XXX | XXX |
| EV/Revenue | 106.7x | XXX | 192.0x | XXX | XXX | XXX |
| EV/EBITDA | -13.9x | XXX | -16.3x | XXX | XXX | XXX |
| EV/EBIT | -12.7x | XXX | -14.0x | XXX | XXX | XXX |
| EV/Gross Profit | 156.0x | XXX | n/a | XXX | XXX | XXX |
| P/E | -12.0x | XXX | -13.9x | XXX | XXX | XXX |
| EV/FCF | -12.1x | XXX | -14.5x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Start Free Trial4basebio's last 12 month revenue growth is 218%
4basebio's revenue per employee in the last FY averaged $16K, while opex per employee averaged $0.2M for the same period.
4basebio's rule of 40 is -1233% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
4basebio's rule of X is -224% (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
See operational valuation multiples for 4basebio and other 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue Growth | 218% | XXX | 211% | XXX | XXX | XXX |
| EBITDA Margin | -770% | XXX | -1176% | XXX | XXX | XXX |
| EBITDA Growth | 10% | XXX | n/a | XXX | XXX | XXX |
| Rule of 40 | -1233% | XXX | -958% | XXX | XXX | XXX |
| Bessemer Rule of X | XXX | XXX | -224% | XXX | XXX | XXX |
| Revenue per Employee | XXX | XXX | $16K | XXX | XXX | XXX |
| Opex per Employee | XXX | XXX | $0.2M | XXX | XXX | XXX |
| S&M Expenses to Revenue | XXX | XXX | 38% | XXX | XXX | XXX |
| G&A Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| R&D Expenses to Revenue | XXX | XXX | 502% | XXX | XXX | XXX |
| Opex to Revenue | XXX | XXX | 1439% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Julphar | XXX | XXX | XXX | XXX | XXX | XXX |
| Benevolent AI | XXX | XXX | XXX | XXX | XXX | XXX |
| Galapagos | XXX | XXX | XXX | XXX | XXX | XXX |
| Pharming | XXX | XXX | XXX | XXX | XXX | XXX |
| Vivoryon Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
4basebio acquired XXX companies to date.
Last acquisition by 4basebio was XXXXXXXX, XXXXX XXXXX XXXXXX . 4basebio acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Start Free Trial| When was 4basebio founded? | 4basebio was founded in 2019. |
| Where is 4basebio headquartered? | 4basebio is headquartered in United Kingdom of Great Britain and Northern Ireland. |
| How many employees does 4basebio have? | As of today, 4basebio has 77 employees. |
| Who is the CEO of 4basebio? | 4basebio's CEO is Dr. Heikki Lanckriet, PhD. |
| Is 4basebio publicy listed? | Yes, 4basebio is a public company listed on LON. |
| What is the stock symbol of 4basebio? | 4basebio trades under 4BB ticker. |
| When did 4basebio go public? | 4basebio went public in 2021. |
| Who are competitors of 4basebio? | Similar companies to 4basebio include e.g. Julphar, Benevolent AI, Galapagos, Pharming. |
| What is the current market cap of 4basebio? | 4basebio's current market cap is $231M |
| What is the current revenue of 4basebio? | 4basebio's last 12 months revenue is $2.3M. |
| What is the current revenue growth of 4basebio? | 4basebio revenue growth (NTM/LTM) is 218%. |
| What is the current EV/Revenue multiple of 4basebio? | Current revenue multiple of 4basebio is 106.7x. |
| Is 4basebio profitable? | Yes, 4basebio is EBITDA-positive (as of the last 12 months). |
| What is the current EBITDA of 4basebio? | 4basebio's last 12 months EBITDA is -$17.4M. |
| What is 4basebio's EBITDA margin? | 4basebio's last 12 months EBITDA margin is -770%. |
| What is the current EV/EBITDA multiple of 4basebio? | Current EBITDA multiple of 4basebio is -13.9x. |
| What is the current FCF of 4basebio? | 4basebio's last 12 months FCF is -$20.0M. |
| What is 4basebio's FCF margin? | 4basebio's last 12 months FCF margin is -885%. |
| What is the current EV/FCF multiple of 4basebio? | Current FCF multiple of 4basebio is -12.1x. |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
